Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business DevelopmentsPRNewsWire • 11/09/22
These Were the Five Best and Worst Performing Small-cap Stocks in October 202224/7 Wall Street • 11/08/22
Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 11/01/22
Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale UniversityPRNewsWire • 10/25/22
Biohaven Ltd. (BHVN) Surges 7.6%: Is This an Indication of Further Gains?Zacks Investment Research • 10/07/22
Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for PatientsPRNewsWire • 10/04/22
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key TestInvestors Business Daily • 09/29/22
Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)PRNewsWire • 09/29/22
Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODTPRNewsWire • 08/31/22
Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health TreatmentsBusiness Wire • 08/23/22
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, VIVO, HNGR, CMAXPRNewsWire • 08/15/22
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/05/22
Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business DevelopmentsPRNewsWire • 08/05/22
American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each OtherPRNewsWire • 07/28/22